{"entity":{"id":"nct06660654","kind":"trial","name":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","aka":[],"tldr":"A phase 2 trial of Raludotatug deruxtecan in advanced solid tumours, run by Daiichi Sankyo, active and no longer recruiting.","summary":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) is a phase 2 interventional study registered as NCT06660654 by Daiichi Sankyo, with 200 participants enrolled, started 2025-01-06 and due to reach its primary completion in 2027-09-30. Interventions recorded: Raludotatug deruxtecan.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06660654","url":"https://clinicaltrials.gov/study/NCT06660654"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["raludotatug-deruxtecan"],"companies":["daiichi-sankyo","merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06660654","phase":"2","setting":"REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors","sponsor":"Daiichi Sankyo","enrolled":200,"outcomes":[]},"route":"/trials/nct06660654/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}